Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196): evaluation report
Evaluation Report: contents
01. Pre-Meeting Briefing prepared by NICE
02. Submission from the technology manufacturer – Novartis
03. NICE request to the manufacturer for clarification on their submission
04. Manufacturer clarification request
05. Consultee submission – GIST Support UK
06. Consultee submission – Sarcoma UK
07. Patient expert personal perspective – Dore
08. Patient expert personal perspective – Puntis
09. Clinical expert personal perspective – Wong
10. Clinical expert personal perspective – Judson
11. Evidence Review Group report prepared by SHTAC
12. Erratum To the Evidence Review Group report
13. Manufacturer factual accuracy check of Evidence Review Group report
14. Evidence Review Group response to manufacturer factual accuracy check
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report. It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required. If you have any feedback on the new format please contact the Project Manager for this appraisal.
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196): evaluation report
27 June 2014 (8.56 Mb 33 sec) |
This page was last updated: 27 June 2014